On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the Section 503A Bulks List and recommended six of them. The committee voted against the recommendation of the FDA’s own multidisciplinary review team, which had advised against all seven.
Coverage since has run from “the FDA approved BPC-157” to “nothing changed.” Both are wrong. Here is the record.
What the committee voted
| Substance | Day | Vote | Outcome |
|---|---|---|---|
| BPC-157 | July 23 | 8-6, 1 abstention | Recommended |
| KPV | July 23 | 8-6, 1 abstention | Recommended |
| TB-500 | July 23 | 8-6, 1 abstention | Recommended |
| MOTS-c | July 23 | 7-5, 2 abstentions | Recommended |
| Semax | July 24 | 8-5, 1 abstention | Recommended |
| Epitalon | July 24 | 7-5, 1 abstention | Recommended |
| Emideltide (DSIP) | July 24 | 6-7, 1 abstention | Not recommended |
Emideltide was the only rejection. Reported counts for Epitalon vary between outlets, with STAT reporting 7-4 and trade coverage reporting 7-5 with one abstention. The other six counts are consistent across sources.
What the 503A Bulks List actually is
Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by licensed pharmacies. A bulk drug substance can be compounded under 503A if it appears in a USP or NF monograph, is a component of an FDA-approved drug, or appears on a list the FDA maintains by regulation. That third route is the 503A Bulks List, and it is what the committee was voting on.
Two limits follow from the statute. A substance on that list can be compounded by a licensed pharmacy against a prescription for an identified patient. Listing is not drug approval, does not establish that a substance is safe or effective, and does not create a retail channel. The approval pathway remains what it has always been: an investigational new drug application, clinical trials, and a new drug application.
Why the FDA’s review team said no
The agency’s reviewers recommended against every one of the seven. Their central objection was identity, and it is a chemistry problem rather than a policy position.
Reviewers argued that nobody can write meaningful quality standards for a substance whose composition is unsettled. Material sold under the name BPC-157 varies in amino acid count, and no salt, ester, or free base form serves as the reference. A pharmacy compounding from a substance with no fixed identity has no standard to compound against and no way to show that one lot matches another.
Reviewers raised further concerns on individual substances, including a potential cancer signal associated with TB-500 despite the absence of studies on TB-500 itself, risks specific to injectable preparation, and an absence of efficacy data across the set.
None of these objections disappeared when the committee voted. They become the FDA’s own record during rulemaking.
What happens next
The vote is advisory. It binds nobody, and the FDA has declined advisory committee recommendations before.
For any of the six to become compoundable, the FDA has to accept the recommendation, publish a notice of proposed rulemaking, take public comment over a window that runs 60 to 90 days in most rulemakings, review that comment, and issue a final rule. Legal analysts put the full sequence at 12 to 24 months. The agency can move faster through an interim designation or a stated enforcement position, but it cannot skip notice-and-comment rulemaking.
Until a final rule publishes, none of the six is legal to compound. The July vote changed the record in front of the FDA. It did not change the law.
What the vote does not do
Most of the confusion sits in the gap between the headlines and the docket, so take the list one item at a time.
The vote did not approve any of these substances as drugs. It did not find any of them safe or effective. It did not authorize sale to the public, and it did not create any lawful route for a consumer to obtain them. It applies to licensed 503A compounding pharmacies acting on a prescription, and only if a final rule issues.
Every compound named in this post remains an unapproved substance supplied for laboratory research. Vantage Aminos sells research materials to research buyers, and nothing in the July proceeding alters that. The FDA has stated its position on sellers who blur the two: in warning letters issued March 31, 2026, the agency held that a research use only label does not control when a seller’s own marketing shows an intent for human use.
Reading the docket yourself
The FDA publishes its briefing materials, the meeting agenda, and the transcript for every advisory committee meeting. The briefing document for this meeting sets out the review team’s full analysis of each substance, and it is the most detailed public account of the identity and characterization problem available. Both are linked below.
ReferencesSources
- FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Agenda and meeting materials.
- FDA, Briefing Document, Pharmacy Compounding Advisory Committee. Review team analysis of all seven substances.
- Hyman, Phelps & McNamara, PCAC Approves Four Bulk Drug Substances for the 503A List. Day 1 votes and the review team position.
- STAT, FDA advisory panel narrowly votes to allow compounding of unapproved peptides, July 23, 2026.
- STAT, FDA advisory panel narrowly rejects compounding of one peptide, backs two others, July 24, 2026.
- Orrick, FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting. Rulemaking procedure and timeline.
- FDA, Warning Letter, Mile High Compounds LLC, 03/31/2026. Intended use and research use only labeling.
For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
- HPLC + MS tested, every batch
- U.S. synthesized
- Batch COA on the product page